← Browse by Condition
Medical Condition

breast neoplasms

Total Trials
22
Recruiting Now
22
Trial Phases
Phase 2, Phase 3, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for breast neoplasms sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — breast neoplasms Clinical Trials

How many clinical trials are currently recruiting for breast neoplasms?
ClinicalMetric currently tracks 22 actively recruiting clinical trials for breast neoplasms, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 22. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for breast neoplasms?
breast neoplasms research spans Phase 1 (1 trial), Phase 2 (4 trials), Phase 3 (4 trials), Phase 4 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a breast neoplasms clinical trial?
Eligibility criteria for breast neoplasms trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
4
Phase 3
4
Phase 4
1
Top Sponsors
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 3 trials
Hubei Cancer Hospital 1 trial
Concure Oncology-Breast Microseed Inc. 1 trial
Jae Yong Jeon, MD 1 trial
AC Camargo Cancer Center 1 trial

Recruiting Clinical Trials

NCT06319157
Recruiting
Minimal Access Versus Conventional Latissimus Dorsi Flap Harvest for Breast Reconstruction
Enrollment
94 pts
Location
China
Sponsor
Sun Yat-Sen Memorial Hospital ...
View Trial →
NCT07264998
Recruiting
Observational Study of Gut Microbiota in Abemaciclib-Treated Patients With and Without Diarrhea
Enrollment
60 pts
Location
China
Sponsor
Hubei Cancer Hospital
View Trial →
NCT02701244
Recruiting
A Registry Study of Breast Microseed Treatment
Enrollment
420 pts
Location
United States
Sponsor
Concure Oncology-Breast Micros...
View Trial →
NCT07595718
Recruiting
AI-Based Phenome Data Analysis for Predicting the Onset of Major Diseases
Enrollment
1,000 pts
Location
South Korea
Sponsor
Jae Yong Jeon, MD
View Trial →
NCT04993014 Phase 2
Recruiting
Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer
Enrollment
80 pts
Location
Brazil
Sponsor
AC Camargo Cancer Center
View Trial →
NCT05430399 Phase 3
Recruiting
Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer
Enrollment
349 pts
Location
China
Sponsor
Sun Yat-sen University
View Trial →
NCT06739655
Recruiting
Preoperative Radiation Therapy and Immediate Breast Reconstruction
Enrollment
180 pts
Location
Belgium
Sponsor
Cancer Research Antwerp
View Trial →
NCT05981014 Phase 1, Phase 2
Recruiting
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
Enrollment
196 pts
Location
China
Sponsor
Sun Yat-Sen Memorial Hospital ...
View Trial →
NCT06702800
Recruiting
Clinical Exploratory Study on Predicting Drug Sensitivity for Breast Cancer Treatment Using Simulated Organoid Models.
Enrollment
30 pts
Location
China
Sponsor
Xiangya Hospital of Central So...
View Trial →
NCT07297927
Recruiting
Prospective Study on ICG Lymphoscintigraphy Changes Before and After Radiotherapy in Breast Cancer Patients
Enrollment
40 pts
Location
South Korea
Sponsor
Inah Kim
View Trial →
NCT07158164 Phase 4
Recruiting
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment
Enrollment
100 pts
Location
United States
Sponsor
Rutgers, The State University ...
View Trial →
NCT04052893
Recruiting
DFS and QOL After Modified Radical Mastectomy vs. Expanded Mckissock Surgery for EIC of the Breast
Enrollment
200 pts
Location
China
Sponsor
Shengjing Hospital
View Trial →
NCT07500428
Recruiting
Construction of a Benchmark for Breast Ultrasound AI Interpretation and Performance Evaluation of Multimodal AI Models
Enrollment
1,380 pts
Location
China
Sponsor
Peking Union Medical College H...
View Trial →
NCT05327543
Recruiting
Effects of Online Yoga on the Quality of Life of Breast Cancer Patients
Enrollment
138 pts
Location
Germany
Sponsor
Charite University, Berlin, Ge...
View Trial →
NCT04816006
Recruiting
Breast Cancer, Reasoning, and Activity Intervention
Enrollment
160 pts
Location
United States
Sponsor
Mayo Clinic
View Trial →
NCT07060807 Phase 3
Recruiting
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Enrollment
1,000 pts
Location
United States, Argen...
Sponsor
Merck Sharp & Dohme LLC
View Trial →
NCT02732860
Recruiting
Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host
Enrollment
120 pts
Location
Canada
Sponsor
University Health Network, Tor...
View Trial →
NCT06875414
Recruiting
Breast Cancer and Resilience in Couple
Enrollment
40 pts
Location
Italy
Sponsor
Regina Elena Cancer Institute
View Trial →
NCT07287098 Phase 2
Recruiting
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Enrollment
600 pts
Location
United States, Belgi...
Sponsor
Eli Lilly and Company
View Trial →
NCT06926868 Phase 2, Phase 3
Recruiting
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Enrollment
500 pts
Location
United States, Argen...
Sponsor
Bristol-Myers Squibb
View Trial →
NCT06421285
Recruiting
Effect of Preoperative Exercise on the Prevention of Secondary Lymphedema in Breast Cancer Patients
Enrollment
60 pts
Location
South Korea
Sponsor
Asan Medical Center
View Trial →
NCT06313463 Phase 3
Recruiting
Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy
Enrollment
375 pts
Location
China
Sponsor
Sun Yat-Sen Memorial Hospital ...
View Trial →

Related Conditions

cancer (2) colorectal neoplasms (2) breast cancer (2) hormone receptor positive breast cancer (1) abemaciclib (1) abemaciclib related diarrhea (1) drug induced diarrhea (1) gastrointestinal microbiome focus (1) microbiome (1) diabetes mellitus type 2 (1) low back pain (1) osteoarthritis (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology